

Date: 2<sup>nd</sup> April 2025  
Ref: CORP 2025 - 049

Dear xxx

**Freedom of Information request: Treatment of breast and endometrial cancers (CORP 2025 - 049)**

Thank you for your request for information which the Trust received on 4<sup>th</sup> March 2025

Your Request and the Trust's response is contained in Appendix 1 below.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff / Caerdydd  
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor,  
Churchill House,  
Churchill Way,  
Cardiff,  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.




Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



## APPENDIX 1

### BREAST CANCER

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	19
1.2 Alpelisib (Piqray)	10
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	51
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	160
1.7 Ribociclib (Kisqali)	72
1.8 Capiwasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	<6*

**Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?**

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	0
2.2 Ribociclib (Kisqali)	0
2.3 Olaparib (Lynparza)	<6*

**Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?**

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	0
3.2 Ribociclib (Kisqali)	0

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

**Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?**

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	0
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	160
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	0

**Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024?**

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	
5.2 Locally advanced or metastatic breast cancer	Information not held

\* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

## ENDOMETRIAL CANCER

**Please note Endometrial diagnosis incorporates cervical and other gynae cancers (we are unable to split out within the time limit so have answered including other cancers).**

It is formally recorded in different systems, linking the data isn't always straightforward (i.e. in cases where a patient has had >1 referral to VCS for different cancers, if we're linking the chemotherapy data we've used for this request, we'd need to make sure we're pulling the diagnosis for the same episode of care (e.g. we're not counting patients who have previously been treated for endometrial cancer, but are now being treated by us for a different cancer).

**Q6. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
6.1 Dostarlimab (Jemperli)	<6*
6.2 Pembrolizumab (Keytruda)	<6*
6.3 Lenvatinib (Lenvima)	9

**Q7. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
7.1 Dostarlimab monotherapy	<6*
7.2 Dostarlimab in combination with Chemotherapy	0
7.3 Pembrolizumab monotherapy	<6*
7.4 Pembrolizumab + Lenvatinib in combination	9
7.5 Lenvatinib monotherapy	0

\* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.